8.18
price up icon2.63%   0.21
after-market アフターアワーズ: 8.22 0.04 +0.49%
loading
前日終値:
$7.97
開ける:
$7.97
24時間の取引高:
2.91M
Relative Volume:
2.91
時価総額:
$396.93M
収益:
$89.04M
当期純損益:
$-241.08M
株価収益率:
-1.5551
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
+3.28%
1か月 パフォーマンス:
+38.88%
6か月 パフォーマンス:
-23.34%
1年 パフォーマンス:
-48.03%
1日の値動き範囲:
Value
$7.78
$9.02
1週間の範囲:
Value
$6.89
$9.02
52週間の値動き範囲:
Value
$5.035
$16.85

Regenxbio Inc Stock (RGNX) Company Profile

Name
名前
Regenxbio Inc
Name
セクター
Healthcare (1148)
Name
電話
240-552-8181
Name
住所
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
職員
353
Name
Twitter
@REGENXBIO
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
RGNX's Discussions on Twitter

RGNX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RGNX
Regenxbio Inc
8.18 396.93M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
432.00 115.57B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
574.16 60.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
542.47 37.56B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.86 35.18B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
224.73 26.10B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-11 ダウングレード Goldman Buy → Neutral
2025-02-07 再開されました Raymond James Outperform
2024-11-15 再開されました Morgan Stanley Overweight
2024-10-10 再開されました Raymond James Outperform
2024-06-07 開始されました Goldman Buy
2024-03-11 開始されました H.C. Wainwright Buy
2024-03-08 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-03-06 アップグレード Leerink Partners Market Perform → Outperform
2024-02-21 再開されました Raymond James Outperform
2023-11-01 開始されました Stifel Buy
2023-06-02 開始されました Robert W. Baird Outperform
2022-06-23 開始されました Berenberg Buy
2021-12-15 開始されました Wedbush Neutral
2021-10-19 再開されました Morgan Stanley Overweight
2021-01-06 アップグレード Raymond James Outperform → Strong Buy
2020-12-16 開始されました UBS Buy
2020-06-25 再開されました BofA/Merrill Buy
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2019-08-20 アップグレード SVB Leerink Underperform → Mkt Perform
2019-06-18 繰り返されました Chardan Capital Markets Buy
2019-06-14 再開されました Raymond James Outperform
2019-06-05 繰り返されました Chardan Capital Markets Buy
2019-02-25 アップグレード Evercore ISI In-line → Outperform
2019-02-05 アップグレード Raymond James Outperform → Strong Buy
2018-12-17 繰り返されました Chardan Capital Markets Buy
2018-11-08 繰り返されました BofA/Merrill Neutral
2018-08-08 繰り返されました Chardan Capital Markets Buy
2018-07-23 ダウングレード BofA/Merrill Buy → Neutral
2018-07-10 繰り返されました Chardan Capital Markets Buy
2018-05-09 繰り返されました Barclays Overweight
2018-04-09 繰り返されました Chardan Capital Markets Buy
2018-03-12 ダウングレード Evercore ISI Outperform → In-line
2018-02-13 開始されました Mizuho Neutral
2017-11-09 再開されました Morgan Stanley Overweight
すべてを表示

Regenxbio Inc (RGNX) 最新ニュース

pulisher
May 13, 2025

Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN

May 13, 2025
pulisher
May 13, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com

May 13, 2025
pulisher
May 13, 2025

Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

Regenxbio BLA for Hunter syndrome candidate accepted by FDA - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus

May 13, 2025
pulisher
May 13, 2025

FDA sets review date for potential Hunter syndrome gene therapy - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Regenxbio Inc (RGNX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Regenxbio Inc earnings missed by $0.36, revenue fell short of estimates - Investing.com India

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Reports Strong Q1 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights - Eagle-Tribune

May 12, 2025
pulisher
May 12, 2025

Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Regenxbio: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

REGENXBIO Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus

May 12, 2025
pulisher
May 09, 2025

What to Expect from Regenxbio's Earnings - Nasdaq

May 09, 2025
pulisher
May 08, 2025

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting - Citizen Tribune

May 08, 2025
pulisher
May 08, 2025

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting | RGNX Stock News - GuruFocus

May 08, 2025
pulisher
May 06, 2025

REGENXBIO to Participate in Upcoming Investor Conferences - Eagle-Tribune

May 06, 2025
pulisher
May 06, 2025

REGENXBIO to Participate in Upcoming Investor Conferences | RGNX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

May 05, 2025
pulisher
May 02, 2025

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights - Citizen Tribune

May 02, 2025
pulisher
May 01, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth - simplywall.st

May 01, 2025
pulisher
May 01, 2025

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail

May 01, 2025
pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

REGENXBIO to Host Conference Call on May 12 to Discuss First Qua - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

REGENXBIO Q1 2025 Earnings Call: Financial Results and Key Operations Update Coming May 12 - Stock Titan

Apr 30, 2025
pulisher
Apr 30, 2025

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights | RGNX Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 27, 2025

Investor Network: REGENXBIO, Inc. to Host Earnings Call - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Regenxbio Inc’s Market Journey: Closing Weak at 5.93, Down -5.72 - DWinneX

Apr 27, 2025
pulisher
Apr 26, 2025

REGENXBIO, Inc. to Host Earnings Call - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st

Apr 24, 2025
pulisher
Apr 24, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Geode Capital Management LLC - Defense World

Apr 24, 2025
pulisher
Apr 22, 2025

Form 8-KCurrent report - ADVFN

Apr 22, 2025
pulisher
Apr 21, 2025

Regenxbio (RGNX) Gains Following Positive FDA Comments on Gene Therapies - GuruFocus

Apr 21, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Apr 17, 2025
pulisher
Apr 08, 2025

RGNX stock touches 52-week low at $5.6 amid sharp annual decline - Investing.com Nigeria

Apr 08, 2025
pulisher
Apr 07, 2025

RGNX stock touches 52-week low at $5.6 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 02, 2025

When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India

Mar 31, 2025

Regenxbio Inc (RGNX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$65.71
price down icon 3.01%
$19.31
price down icon 3.11%
$32.82
price down icon 1.59%
$24.61
price down icon 2.57%
$94.50
price down icon 2.85%
biotechnology ONC
$224.73
price down icon 3.65%
大文字化:     |  ボリューム (24 時間):